---
title: "JBM Healthcare publishes FY2026 annual report"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292767985.md"
description: "JBM Healthcare released its FY2026 annual report, highlighting resilient performance amid improving Hong Kong retail conditions. Growth was driven by proprietary Chinese medicines and double-digit expansion in Oncotype DX genomic testing, while health and wellness revenue declined due to product rationalization. The company is sharpening its strategy toward owned brands in cross-border e-commerce and expanding downstream clinic services through acquisitions to support vertical integration."
datetime: "2026-07-15T12:35:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292767985.md)
  - [en](https://longbridge.com/en/news/292767985.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292767985.md)
generator: "portal-rs"
---

# JBM Healthcare publishes FY2026 annual report

-   JBM Healthcare published its 2025⁄2026 annual report, flagging resilient performance as Hong Kong retail conditions improved. \* Proprietary Chinese medicines drove growth, supported by continued momentum in core heritage brands and portfolio expansion. \* Health and wellness revenue fell on product rationalization, partly offset by double-digit growth in Oncotype DX genomic testing. \* Strategy sharpened toward owned brands in cross-border e-commerce, with wider reach via major mainland platforms. \* Acquisitions expanded downstream Chinese medicine clinic services, adding a clinic network to support vertical integration across products, practitioners, and patients. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JBM (Healthcare) Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260715-12245633), on July 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [02161.HK](https://longbridge.com/en/quote/02161.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [JBM Healthcare releases 2025/2026 ESG report](https://longbridge.com/en/news/292771023.md)
- [04:43 ETDe la vente de produits au récit d'histoires : comment un documentaire transforme le commerce en dialogue culturel](https://longbridge.com/en/news/297622647.md)
- [Opus Genetics to report Phase 1/2 Cohort 1 topline data for OPGx-BEST1 gene therapy Sept. 9 webcast](https://longbridge.com/en/news/297773739.md)
- [Will we "see" you in New York at Moody's Capital 2026 Disruptive Growth and Life Sciences Conference September 9-10 | GGII Stock News](https://longbridge.com/en/news/297500083.md)
- [NeuroGT Announces FDA Clearance of Investigational New Drug Application for NGT-104, an AAV9 Gene Replacement Product for MPS IIIB](https://longbridge.com/en/news/297947685.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**